EC
Euclidean Capital, the family office of James Simons, focuses on long-term capital preservation and growth through a disciplined investment approach. The firm invests across public and private markets, alternative investments, and philanthropic initiatives, with a notable preference for biotech, life sciences, financial services, and increasingly, AI and machine learning companies.
Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $70.2M (across 16 rounds with reported amounts).
Portfolio
16
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ripple Foods | Unknown | $17M | Dec 2025 |
| LLeal Therapeutics, Inc. | Series A | $30M | Aug 2025 |
| LLeal Therapeutics, Inc. | Series B | $45M | Oct 2024 |
 FundGuard | Series C | $100M | Mar 2024 |
 April | Series A | $30M | Jun 2022 |
| April | Series A | $30M | Jun 2022 |
 Possible Finance | Series B | $20M | May 2022 |
 Duality | Series B | $30M | Oct 2021 |
| Ripple Foods | Series E | $60M | Sep 2021 |
 ASAPP | Series C | $120M | May 2021 |
 A2 Biotherapeutics | Series B | $71.5M | Oct 2020 |
| ASAPP | Series B | $185M | May 2020 |
| PPeltarion | Series A | $20M | Feb 2019 |
| Ripple Foods | Series C | $65M | Jan 2018 |
 23andMe | Series D | $250M | Sep 2017 |
| DDascena Inc. | Series B | $50M | — |
Top Co-Investors
Team83 shared
S2G Ventures2 shared
Prelude Ventures2 shared
Tao Capital Partners2 shared
OrbiMed2 shared
Alexandria Venture Investments2 shared
Casdin Capital2 shared
Treasury2 shared
QED2 shared
Nyca2 shared
Emergence Capital2 shared
March Capital Partners2 shared
HOF Capital2 shared
Telstra Ventures2 shared
LG1 shared
Intel Capital1 shared
Hearst Ventures1 shared
Material Impact1 shared
Hamilton Lane1 shared
Frazier Healthcare Partners1 shared
Last updated: 12 April 2026